Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs

Fungal Genetics and Biology

Volumn 78, Issue , 2015, Pages 93-98

  Krysan, Damian J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Antifungal drugs; Cryptococcus; Drug repurposing

Indexed keywords

1,2 BENZISOTHIAZOLINONE; AMIODARONE; AMPHOTERICIN B; ANTI CRYPTOCOCCAL AGENT; ASTEMIZOLE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; MILTEFOSINE; POLYMYXIN B; SERTRALINE; T 2307; TAMOXIFEN; THIORIDAZINE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT;

AIDS PATIENT; ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CONCENTRATION RESPONSE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GRUBII; CRYPTOCOCCUS NEOFORMANS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG REPOSITIONING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FILOBASIDIELLA; FUNGICIDAL ACTIVITY; GOLD STANDARD; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENINGOENCEPHALITIS; MINIMUM FUNGICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS; DRUG DEVELOPMENT; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROCEDURES; TRENDS;

CRYPTOCOCCUS NEOFORMANS VAR. GRUBII; CRYPTOCOCCUS NEOFORMANS VAR. NEOFORMANS;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS;

EID: 84937950084     PISSN: 10871845     EISSN: 10960937     Source Type: Journal    
DOI: 10.1016/j.fgb.2014.12.001     Document Type: Article

References (39)

1. Abbate E., Vescovo M., Natiello M., Cufre M., Garcia A., Gonzalez Montaner P., Ambroggi M., Ritacco V., van Soolingen D. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin, and thioridazine. J. Antimicrob. Chemother. 2012, 67:473-477.
2. Alex D., Fay-Andrieu F., May J., Thampi L., Dou D., Mooney A., Groutas W., Calderone R. Amino acid-derived 1,2-benisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets. Antimicrob. Agents Chemother. 2012, 56:4630-4639.
3. Balgi A.D., Fonesca B.D., Donahue E., Tsang T.C.F., Lajoie P., Proud C.G., Nabi I.R., Roberge M. Screen for specific modulators of autophagy reveals novel therapeutic inhibitors of TORC1 signaling. PLoS ONE 2009, 4:e7124.
4. Bicanic T., Muzoora C., Brouwer A.E., Meintjes G., Longley N., Taseera K., Rebe K., Loyse A., Jarivis J., Bekker L.G., Wood R., Limmathurostakul D., Chierakul W., Stepniewska K., White N.J., Jaffar S., Harrison T.S. Independent association of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of combined cohort of 262 patients. Clin. Infect. Dis. 2009, 49:702-709.
5. Bisson W. Drug repurposing in chemical genomics: can we learn from the past to improve the future?. Curr. Top. Med. Chem. 2012, 12:1867-1868.
6. Butts A., Krysan D.J. Antifungal drug discovery: something old and something new. PLoS Pathog. 2012, 8:e1002870.
7. Butts A., DiDone L., Koselny K., Baxter B.K., Chabrier-Rosello Y., Wellington M., Krysan D.J. A re-purposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot. Cell 2013, 12:278-287.
8. Butts A., Koselny K., Chabrier-Roselló Y., Semighini C.P., Brown J.C.S., Wang X., Annadurai S., DiDon L., Tabroff J., Childers W.E., Abou-Gharbia M., Wellington M., Cardenas M.E., Madhani H.D., Heitman J., Krysan D.J. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF-hand proteins and synergize with fluconazole in vivo. mBio 2014, 5:e00765.
9. Chayakulkeeree M., Perfect J.R. Cryptococcosis. Infect. Dis. Clin. N. Am. 2006, 20:507-544.
10. Chong C.R., Chen X., Shi L., Liu J.O., Sullivan D.J. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2006, 2:415-416.
11. Day J.N., Chau T.T., Wolbers M., et al. Combination therapy for cryptococcal meningitis. N. Engl. J. Med. 2013, 368:1291-1302.
12. DiDone L., Scrimale T., Baxter B.K., Krysan D.J. A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis. Nat. Protoc. 2010, 5:1107-1114.
13. Dou D., Alex D., Du B., Tiew K.C., Aravapalli S., Mandadapu S.R., Calderone R., Groutas W.C. Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives. Bioorg. Med. Chem. 2011, 19:5782-5787.
14. Gabaldon T., Huynen M.A. Lineage-specific gene loss following mitochondrial endosymbiosis and its potential for function prediction in eukaryotes. Bioinformatics 2005, 21:S144-150.
15. Gamarra S., Rocha E.M., Zhang Y.Q., Parks S., Rao R., Perlin D. Mechanism of synergistic effect of amiodarone and fluconazole in C. albicans. Antimicrob. Agents Chemother. 2010, 54:153-1761.
16. Hata K., Horii T., Miyazaki M., Watanabe N.A., Okubo M., Sonoda J., Nakamoto K., Tanaka K., Shirotori S., Murai N., Inoue S., Matsukura M., Abe S., Yoshimatsu K., Asada M. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis and fusariosis. Antimicrob. Agents Chemother. 2011, 55:4543-4551.
17. Lein E.A., Wester K., Lonning P.E., Solheim E., Ueland P.M. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer 1991, 63:641-645.
18. Mitsuyama J., Nomura N., Hashiomoto K., Yamada E., Nishikawa H., Kaeriyama M., Kimura A., Todo Y., Narita H. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob. Agents Chemother. 2008, 52:1318-1324.
19. Ordway D., Viveiros L., Bettencourt R., Aleida J., Martins M., Kristiansen J.E., Molnar J., Amaral L. Clinical concentrations of thioridazine kill intracellular multi-drug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2003, 47:917-922.
20. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
21. Perfect J.R. Efficiently killing a sugar-coated yeast. N. Engl. J. Med. 2013, 368:1354-1356.
22. Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., Harrison T.S., Larsen R.A., Lortholary O., Nguyen M.H., Pappas P.G., Powderly W.G., Singh N., Sobel J.D., Sorrell T.C. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2010, 50:291-322.
23. Ravu R.R., Chen Y.L., Jacob M.R., Pan X., Agarwal A.K., Khan S.I., Heitman J., Clark A.M., Li X.C. Synthesis and antifungal activities of miltefosine analogs. Bioorg. Med. Chem. Lett. 2013, 23:4828-4831.
24. Robinson S.P., Langan-Fahey S.M., Johnson D.A., Jordan V.C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos. 1991, 19:36-43.
25. Roemer T., Krysan D.J. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb. Perspect. Med. 2014, 1:4.
26. Rolston K.V. Cryptococcosis due to Cryptococcus gattii. Clin. Infect. Dis. 2013, 57:552-554.
27. Shibata T., Takahashi T., Yamada E., Kimura A., Nishikawa H., Hayakawa H., Nomura N., Mitsuyama J. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob. Agents Chemother. 2012, 56:5892-5897.
28. Sloan D.J., Dedicoat M.J., Lalloo D.G. Treatment of cryptococcal meningitis in resource-limited settings. Curr. Opin. Infect. Dis. 2009, 22:455-463.
29. Spitzer M., Griffiths E., Blakely K.M., Wildenhain J., Tyers M., Wright G.D. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 2011, 7:499.
30. Steinbach W.J., Reedy J.L., Cramer R.A., Perfect J.R., Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat. Rev. Microbiol. 2007, 5:418-430.
31. Strittmatter S.M. Overcoming drug development bottlenecks with repurposing. Nat. Med. 2014, 20:590-591.
32. Tsukahara K., Hata K., Nakamoto K., Sagane K., Watanabe N.A., Kuromitsu J., Kai J., Tsuchiya M., Ohba F., Jigami Y., Yoshimatsu K., Nagasu T. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol. Microbiol. 2003, 48:1029-1042.
33. Vu K., Gelli A. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. Med. Mycol. 2010, 48:255-262.
34. Wermuth C.G. Selective optimization of side activities: another way for drug discovery. J. Med. Chem. 2004, 47:1303-1314.
35. Widmer F., Wright L.C., Obando D., Handke R., Ganendren R., Ellis D.H., Sorrell T.C. Hexadecylphophocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob. Agents Chemother. 2006, 50:414-421.
36. Wiederhold N.P., Najvar L.K., Bocanegra R., Kirkpatrick W.R., Sorrell T.C., Patterson T.F. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Antimicrob. Agents Chemoether. 2013, 57:745-750.
37. Zhai B., Lin X. Evaluation of the anticryptococcal activity of antibiotic polymixin B in vitro and in vivo. Int. J. Antimicrob. Agents 2013, 41:250-254.
38. Zhai B., Zhou H., Yang L., Zhang J., Giam G.-Z., Xiang X., Lin X. Polymixin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother. 2010, 65:931-938.
39. Zhai B., Wu C., Wang L., Sachs M.S., Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob. Agents Chemother. 2012, 56:3758-3766.